<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20090908002434N8</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-11-15</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of treatment of chronic constipation using combination of Rosa damascene and brown sugar in comparison with polyethylene glycol in children over 12 months old</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of treatment of chronic constipation using combination of Rosa damascene and brown sugar in comparison with polyethylene glycol in children over 12 months old</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/48552</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Eligible people in the study will be randomly assigned to two groups based on a double-blind study. The random allocation will be blockchain,Four-person blocks that we will have 25 blocks.
Twenty-five blocks of four people are selected with random allocation software and people will be assigned to two groups based on these blocks, Blinding description: In this double-blind study, polyethylene glycol syrup in the control group and rose + red sugar syrup based on the evidence of traditional medicine with great effect in the treatment of constipation in the experimental group was used. For this purpose, new patients referred to Imam Reza Clinic of Shiraz University of Medical Sciences After examining and diagnosing constipation, the doctor writes the title of the medicine to treat constipation on the prescription sheet. The patient's initial information is recorded by staff who are also blind, and then the patient is referred to the clinic pharmacy for medication. There, the pharmacy staff, who are blind, give the patient a drug coded by the pharmacist based on a four-item random block table.</study_design>
      <phase>3</phase>
      <hc_freetext>Constipation.</hc_freetext>
      <i_freetext>Intervention 1: "intervention group" rosemary extract and red sugar based on the matching of the desired  active ingredient in which 1cc / kg / day of rose syrup and rose with 1cc / kg / day of polyethylene glycol 40 syrup % Are equal and in terms of appearance both syrups are the same and are in the same containers are used as a treatment for constipation. After receiving the initial dose, at the end of the second week after treatment, they will be examined by a therapist and Basic information is recorded in the questionnaire. If a clinical response is established, treatment with the same dose will continue for another two weeks, and if no response to treatment is observed, treatment is increased to 2cc / kg / day and patients will be re-examined at the end of the fourth week. The fourth week and the final visit, the patients will be re-evaluated. Patients who received 1cc / kg / day of the drug and the dose was not increased will be re-evaluated for symptom response, and patients who received 2cc / kg / day of anti-constipation therapy for response to treatment Will be evaluated. Intervention 2: Control group: 50 children use polyethylene glycol as a treatment for constipation.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After the research and publication of the article, information about the main outcome and the interventions will be shared.

When:
At the end of the study since 2021

To whom:
All physicians and researchers related to the field of pediatrics

Conditions:
For therapeutic and research use, information will be provided to all physicians and researchers

Where to obtain:
Shiraz Namazi Hospital, Pediatric's Department Office, Pediatric Gastroenterology Department

How to obtain:
By referring to  Shiraz Namazi Hospital, Pediatric's Department Office, Pediatric Gastroenterology Department

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abbas Avaz Pour</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shiraz university of medical sciences(central building), Zand Street, Shiraz, Fars</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134874853</zip>
        <telephone>+98 71 3647 4298</telephone>
        <email>abbas.avazpour@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hadi Imanieh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Department of Pediatrics, Namazi Hospital, Namazi Sq</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7134874853</zip>
        <telephone>+98 71 1647 4298</telephone>
        <email>imaniehm@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children over 12 months of age
with Functional Constipation
no underlying disease such as Hirschsprung's disease and metabolic and hypothyroidism</inclusion_criteria>
      <agemin>12 months</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K59.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>constipation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>"intervention group" rosemary extract and red sugar based on the matching of the desired  active ingredient in which 1cc / kg / day of rose syrup and rose with 1cc / kg / day of polyethylene glycol 40 syrup % Are equal and in terms of appearance both syrups are the same and are in the same containers are used as a treatment for constipation. After receiving the initial dose, at the end of the second week after treatment, they will be examined by a therapist and Basic information is recorded in the questionnaire. If a clinical response is established, treatment with the same dose will continue for another two weeks, and if no response to treatment is observed, treatment is increased to 2cc / kg / day and patients will be re-examined at the end of the fourth week. The fourth week and the final visit, the patients will be re-evaluated. Patients who received 1cc / kg / day of the drug and the dose was not increased will be re-evaluated for symptom response, and patients who received 2cc / kg / day of anti-constipation therapy for response to treatment Will be evaluated.</i_keyword>
      <i_keyword>Control group: 50 children use polyethylene glycol as a treatment for constipation</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Defecation less than or equal to two times a week. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Fecal incontinence equal or more than once a week. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>History of stool retention. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>History of hard or painful defecation. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Large fecal mass in the rectum. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>History of thick stools that may block the toilet. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Appetite disorder. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Bad Breath. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
      <prim_outcome>Abdominal pain. Timepoint: Start treatment, two weeks later and four weeks later. Method of measurement: Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-20</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Zand Blvd Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
